Streetbeat News

Products Services

SNGX

Soligenix has been granted FDA Orphan Drug Designation for the active ingredient in SuVax, a subunit protein vaccine aimed at preventing and providing post-exposure prophylaxis against Sudan Ebolavirus (SUDV) infection. This designation is a significant step for Soligenix in the development and potential commercialization of SuVax.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:32 am

MAXN

Maxeon Solar Technologies has launched its new SunPower Performance 7 solar panels, which have received Cradle to Cradle certification. These panels are now available for both residential and commercial customers in the EMEA and APAC regions.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:26 am

ARVN

Arvinas shares surged following a licensing agreement with Novartis for the development and commercialization of ARV-766, aimed at treating prostate cancer. This partnership could potentially enhance Arvinas' financials and market position through milestone payments and royalties, while also accelerating the development and accessibility of ARV-766 to patients.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:25 am

TLSA

Tiziana Life Sciences announced plans to present new quantitative PET imaging data on Foralumab at the upcoming Annual Meeting of the American Academy of Neurology. This presentation could highlight significant advancements in the treatment of neurological conditions, potentially impacting the company's stock.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:24 am

RVSN

Rail Vision has received an initial purchase order of approximately $1M, part of a contract potentially worth up to $5M, for its AI-based Shunting Yard products. These products are slated for installation in Q3 of 2024.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:24 am

LPCN

Lipocine Inc. shares surged following the announcement of positive trial data for LPCN 2401, showing significant body composition improvement in men.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:21 am

ONCY

Oncolytics Biotech has submitted a Type C meeting request to the FDA for Q2 2024 to discuss its planned registration-enabling trial for Pelareorep in HR+/HER2- metastatic breast cancer.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:20 am

JNJ

RLYB

Rallybio's stock price increased following the announcement of a collaboration with Johnson & Johnson to develop therapeutics for pregnant individuals at risk of FNAIT.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:18 am

PRTC

PureTech's LYT-200 has received FDA Fast Track Designation for the treatment of head and neck cancers, indicating a potential acceleration in its development and review process.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:18 am